4D Molecular Therapeutics reported a net margin of -1,929.01% for the quarter ended Jun 2026. These financial ratios cover 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||||||||||||
| EBT Margin | -1,627.09% | -27,256.52% | -2,246.92% | -17,797.53% | -5,140.00% | -2,195.83% | -9,791.95% | -13,188.70% | -49.98% | 169,852.63% | -136,646.43% | -852,800.00% | -1,461,400.00% | -4,965,000.00% | -382,271.43% | -363,980.00% | -63,172.22% | 22.82% | -2,445.91% | -1,924.62% | ||||||
| EBIT Margin | -1,658.93% | -26,917.39% | -2,165.05% | -17,546.91% | -5,299.00% | -2,303.13% | -10,102.68% | -13,446.03% | -69.16% | 192,905.26% | -136,200.00% | -849,120.00% | -1,704,400.00% | -5,611,700.00% | -383,007.14% | -396,373.33% | -67,983.33% | 17.29% | -2,416.15% | -2,037.16% | ||||||
| EBITDA Margin | -1,658.93% | -26,917.39% | -2,165.05% | -17,546.91% | -5,299.00% | -2,303.13% | -10,102.68% | -13,446.03% | -69.16% | 192,905.26% | -136,200.00% | -849,120.00% | -1,704,400.00% | -5,611,700.00% | -383,007.14% | -396,373.33% | -67,983.33% | 17.29% | -2,416.15% | -2,037.16% | ||||||
| Operating Margin | -1,658.93% | -26,917.39% | -2,165.05% | -17,546.91% | -5,299.00% | -2,303.13% | -10,102.68% | -13,446.03% | -69.16% | 192,905.26% | -136,200.00% | -849,120.00% | -1,704,400.00% | -5,611,700.00% | -383,007.14% | -396,373.33% | -67,983.33% | 17.29% | -2,416.15% | -2,037.16% | ||||||
| Net Margin | -1,628.04% | -27,264.13% | -2,160.62% | -17,337.04% | -5,138.20% | -2,195.59% | -9,624.83% | -12,391.63% | -50.76% | 169,910.53% | -115,717.86% | -699,060.00% | -1,461,433.33% | -4,967,100.00% | -342,657.14% | -364,386.67% | -63,195.56% | 22.80% | -2,256.65% | -1,929.01% | ||||||
| FCF Margin | -1,343.78% | -29,273.91% | -2,458.00% | -13,561.73% | -4,596.20% | -1,869.05% | -9,704.03% | -9,569.04% | -7.80% | 132,626.32% | -106,421.43% | -623,380.00% | -1,019,733.33% | -4,681,200.00% | -361,000.00% | -304,826.67% | -51,653.33% | 33.78% | -2,257.79% | -1,850.86% | ||||||
| Efficiency | ||||||||||||||||||||||||||
| Assets AverageAssets Avg. | 247.78M | 297.05M | 339.21M | 313.93M | 291.55M | 271.00M | 252.93M | 298.26M | 357.06M | 350.75M | 484.89M | 625.00M | 612.07M | 582.21M | 538.06M | 494.68M | 448.81M | 495.35M | 539.81M | 502.76M | ||||||
| Invested CapitalInvested Cap. | 505.66M | 427.25M | ||||||||||||||||||||||||
| Asset Utilization RatioAsset Util. | 0.07 | 0.06 | 0.05 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.06 | 0.06 | 0.04 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.16 | 0.18 | ||||||
| Leverage & Solvency | ||||||||||||||||||||||||||
| Debt Ratio | 0.04 | |||||||||||||||||||||||||
| Valuation | ||||||||||||||||||||||||||
| Price to EarningsP/E | -32.94 | -28.19 | -18.52 | -8.05 | -10.14 | -26.47 | -19.92 | -25.64 | -53.07 | -27.03 | -50.30 | -31.18 | -12.82 | -5.14 | -3.12 | -3.17 | -7.15 | 22.27 | -9.22 | -12.81 | ||||||
| Price to SalesP/S | 536.35 | 0.01M | 400.19 | 0.00M | 520.87 | 581.10 | 0.00M | 0.00M | 26.94 | -0.05M | 0.06M | 0.22M | 0.19M | 0.26M | 0.01M | 0.01M | 0.00M | 5.08 | 207.97 | 247.19 | ||||||
| Price to BookP/B | 3.27 | 2.22 | 1.65 | 0.83 | 1.04 | 3.13 | 2.61 | 2.34 | 1.65 | 2.84 | 2.71 | 1.85 | 1.02 | 0.50 | 0.32 | 0.41 | 1.10 | 0.85 | 1.40 | 2.29 | ||||||
| Enterprise Value | 570.98M | 459.23M | 251.68M | -15.10M | 32.72M | 511.08M | 370.89M | 448.90M | 224.57M | 584.47M | 1,103.96M | 547.73M | 60.19M | -169.80M | -171.81M | -119.97M | 101.38M | 29.40M | 242.79M | 573.28M | ||||||
| EV to EBIT | -25.20 | -18.54 | -9.54 | 0.53 | -1.23 | -17.80 | -12.32 | -13.97 | -16.07 | -15.95 | -28.95 | -12.90 | -1.18 | 3.03 | 3.20 | 2.02 | -1.66 | 2.00 | -3.30 | -7.44 | ||||||
| EV to EBITDA | -25.20 | -18.54 | -9.54 | 0.53 | -1.23 | -17.80 | -12.32 | -13.97 | -16.07 | -15.95 | -28.95 | -12.90 | -1.18 | 3.03 | 3.20 | 2.02 | -1.66 | 2.00 | -3.30 | -7.44 | ||||||
| Market Capitalization | 732.66M | 707.01M | 487.83M | 225.99M | 260.43M | 724.64M | 571.34M | 759.24M | 544.24M | 872.70M | 1,629.87M | 1,089.68M | 562.08M | 255.07M | 149.63M | 173.26M | 406.44M | 432.06M | 633.68M | 934.62M | ||||||
| Price to FCFP/FCF | -39.91 | -26.25 | -16.28 | -10.29 | -11.33 | -31.09 | -19.76 | -33.20 | -345.33 | -34.63 | -54.70 | -34.96 | -18.37 | -5.45 | -2.96 | -3.79 | -8.74 | 15.03 | -9.21 | -13.36 | ||||||
| EV to FCF | -31.11 | -17.05 | -8.40 | 0.69 | -1.42 | -21.93 | -12.83 | -19.63 | -142.50 | -23.19 | -37.05 | -17.57 | -1.97 | 3.63 | 3.40 | 2.62 | -2.18 | 1.02 | -3.53 | -8.19 | ||||||
| EV to CFO | -36.32 | -21.03 | -10.69 | 0.76 | -1.56 | -23.01 | -13.29 | -20.34 | -191.78 | -23.71 | -37.95 | -18.11 | -2.05 | 3.70 | 3.60 | 2.77 | -2.18 | 1.03 | -3.56 | -8.19 | ||||||
| Return Ratios | ||||||||||||||||||||||||||
| Return on Sales [ROS]ROS | -1,658.93% | -26,917.39% | -2,165.05% | -17,546.91% | -5,299.00% | -2,303.13% | -10,102.68% | -13,446.03% | -69.16% | 192,905.26% | -136,200.00% | -849,120.00% | -1,704,400.00% | -5,611,700.00% | -383,007.14% | -396,373.33% | -67,983.33% | 17.29% | -2,416.15% | -2,037.16% | ||||||
| Return on Capital Employed [ROCE]ROCE | -28.34% | -25.41% | -24.89% | -34.13% | -38.16% | -43.10% | -47.07% | -41.28% | -30.96% | -34.02% | -25.81% | -21.67% | -28.90% | -33.96% | -39.78% | -47.90% | -55.96% | -35.35% | -36.17% | -43.31% | ||||||
| Return on Assets [ROA]ROA | -26.85% | -23.97% | -24.26% | -32.98% | -36.70% | -40.33% | -43.92% | -38.15% | -27.50% | -29.39% | -23.13% | -19.72% | -25.65% | -29.95% | -35.25% | -40.75% | -47.82% | -29.38% | -30.86% | -36.74% |